Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07199127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Duodenal Polyposis Classification in FAP

Study acronym: DRACO
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia. The DRACO study (Duodenal Risk Assessment in adenomatous polyposis Coli -Oncogene) is a multicenter, STROBE- and CONSORT-compliant cohort study that analyzes upper endoscopies from genetically confirmed FAP patients across independent cohorts to develop, validate, and externally test two multivariable risk models.
Trial Details
NCT Number NCT07199127
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: IRCCS Ospedale San Raffaele
Conditions
(from sponsor)		 Duodenum Cancer, Familial Adenomatous Polyposis, Duodenal Polyposis, Ampulla of Vater Adenoma, FAP Gene Mutation, FAP, Duodenal Neoplasms, Duodenal Adenoma +1 more
Related terms Adenomatous Polyposis Coli, Duodenal Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov